A medical device company named as NeuroMetrix Inc gets Food and Drug Administration (FDA) approval to market its Sensus chronic pain management device in the United State. This device work as transcutaneous electrical nerve stimulator and is very useful for the relief and management of chronic intractable pain.
“This product has attracted attention among health care providers because of its potential benefit to patients suffering from chronic pain,” said Shai N. Gozani M.D., Ph.D., President and Chief Executive Officer of NeuroMetrix. “FDA clearance keeps us on track to launch the SENSUS Pain Management System in the fourth quarter of 2012. We are particularly enthusiastic about adoption of the device by diabetes focused clinicians because a number of recent systematic literature reviews and meta-analyses have concluded that transcutaneous electrical nerve stimulation may be an effective and safe treatment for painful diabetic neuropathy.”
This device is very effective for those patients suffering from a nerve related disorder as diabetic neuropathy. Different medications are being used in diabetic patient for the management of this pain. This device would atleast minimize the use of such medications.
It is estimated that 50% diabetic patients suffer Diabetic neuropathies and its annual cost is approximately $14 billion in United State.
Sensus device is used to worn around the patients’s upper calf and it reduces pain when patient press a button.
“The patient snaps an electrode into the stimulator and then secures the stimulator around the upper calf. Prior to first use, and from time to time, the device is personalized through a quick and straightforward procedure. Pain relief is initiated by simply pressing a button”.
It acts as impulse stimulator and work by inhibiting the signal transmission of pain to the brain.
“Trancutaneous electrical nerve stimulation has been shown to provide pain relief for patients with diabetes”.
Copyright 2012 Medimoon.com. All rights reserved. No part of this site can be reproduced without our written permission.None found.